©FabienMalotYearly results Sanofi ends 2025 on a high, but trims R&D prioritiesParis-based drugmaker Sanofi closed 2025 with strong growth and upbeat guidance, but its latest results also reveal sharp pipeline cuts that underline a tougher phase for R&D choices. more ➔
Lonza GroupCDMOCDMOs dominate the headlines – and Lonza delivers a clear message of strengthCDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined … more ➔
Vetter PharmaCDMOVetter: a multi-million-euro investment for new CDMO facility boost for Saarland/GermanyWith an initial investment of around €480 million, Ravensburg-based Vetter Pharma has now fleshed out its plans to expand operations in Saarlouis, Saarland. The former automotive site is to be redeveloped … more ➔
International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - sAntibody drug conjugatesAfter a turbulent phase: a new milestone from Takeda for Heidelberg PharmaPositive signals from a partnership with Takeda are allowing Heidelberg Pharma to push the setback from a milestone payment not received as planned from Telix somewhat into the background. Nevertheless, … more ➔
Market accessTenpoint wins FDA approval for presbyopia eye drop and raises $235 millionIt’s a busy day for U.K.-based Tenpoint Therapeutics, which has secured U.S. Food and Drug Administration (FDA) approval for YUVEZZI, a combination eye drop for the treatment of presbyopia, while raising … more ➔
RocheRocheRoche: strong growth in all world regions and a full pipeline in late stageRoche made a clear statement in 2025. The Basel-based group increased sales by 7% at constant exchange rates to CHF 61.5bn (€67bn) and lifted core operating profit by as much as 13%. For many observers, … more ➔
Gene therapySensorion raised €60M backed by €20M from Sanofi to advance gene therapies for hearing lossFrench biotech company Sensorion announced today a €60 million (about $72 million) reserved offering including a €20 million strategic investment from Sanofi. The remaining €40 million subscribed … more ➔
Boehringer IngelheimBoehringer IngelheimChina again: Boehringer turns to Shanghai for IBD bispecificBoehringer Ingelheim is continuing its international shopping tour for innovative drug candidates – and once again ends up in China. The German pharmaceutical group has entered into a licensing and … more ➔
Olga Yastremska, New Africa, freepikRecombinasesDresden biotech Seamless lands up to $1.1B Eli Lilly deal for gene therapy hearing lossDresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest … more ➔
MarketFrom cell therapy to combat rifles: Genenta bets its future on becoming Italy’s national-security dealmakerFew biotech pivots are as jarring as Genenta’s latest move. more ➔ The Milan-based company, which went public in late 2021 on the promise of a novel cell-based gene therapy platform, is now effectively … more ➔
©FabienMalot
Lonza Group
Vetter Pharma
International Journal of Molecular Sciences, doi: 10.3390/ijms17040561 JO - s
Roche
Boehringer Ingelheim
Olga Yastremska, New Africa, freepik
